6-hydroxy-4-methyl-benz[1,3]oxathiol-2-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 6-hydroxy-4-methyl-benz[1,3]oxathiol-2-one
• 英文别名: 6-Hydroxy-4-methyl-benz[1,3]oxathiol-2-on；6-hydroxy-4-methyl-1,3-benzoxathiol-2-one；6-hydroxy-4-methyl-2H-1,3-benzoxathiol-2-one
• 化学式: C₈H₆O₃S
• 分子量: 182.2
• InChiKey: QQYJAGMAPKWBJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 作用下， 生成 6-hydroxy-4-methyl-benz[1,3]oxathiol-2-one
  参考文献：
  名称：

  Thiocarbonates of aromatic polyhydroxy compounds

  摘要：

  公开号：

  US02332418A1

文献信息

• Phenyl heterocyclyl ethers
  申请人：——

  公开号：US20030207857A1

  公开（公告）日：2003-11-06

  The invention relates to compounds of formula I 1

  该发明涉及公式I1的化合物。
• [EN] PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS<br/>[FR] DERIVES DE PHENYLE HETEROCYCLYLE ETHER UTILISES COMME INHIBITEURS DU RECAPTAGE DE LA SEROTONINE
  申请人：PFIZER LTD

  公开号：WO2002083643A1

  公开（公告）日：2002-10-24

  The invention relates to compounds of the formula (I) which exhibit activity as selective serotonin re-uptake inhibitors.

  本发明涉及公式（I）的化合物，其表现出作为选择性血清素再摄取抑制剂的活性。
• Neuroprotective benzo 1 3 oxathiol 2 ones
  申请人：Jaquith B. James

  公开号：US20060234987A1

  公开（公告）日：2006-10-19

  This invention relates to benzo[1,3]oxathiol-2-ones, derivatives, and precursors thereof, and their use as neuroprotective agents in the treatment and prevention of neuronal disorders of the central and peripheral nervous systems.

  本发明涉及苯并[1,3]噁硫-2-酮、其衍生物和前体物，以及它们作为神经保护剂在治疗和预防中枢和外周神经系统的神经元疾病中的应用。
• PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS
  申请人：Pfizer Limited

  公开号：EP1377550A1

  公开（公告）日：2004-01-07
• SPT5 INHIBITORS AND USES THEREOF
  申请人：Yeda Research and Development Co. Ltd.

  公开号：US20210379060A1

  公开（公告）日：2021-12-09

  Provided are compounds which are Spt5 inhibitors and which are for use in the treatment diseases and disorders in which inhibiting one or more activities of Spt5 is beneficial, such as, for example, Trinucleotide repeat disorders, obesity, inflammatory diseases, infectious diseases and cancer. The compounds are represented by Formulae I-VII, as defined in the specification.